The operational, financial, and clinical milestones a private biotech must clear before it can credibly go public.
Unlike most industries, biotech companies routinely go public years before generating meaningful revenue — sometimes before a single product is approved. What substitutes for revenue and earnings in the eyes of public investors is a credible clinical data package and a differentiated pipeline story: evidence that the science works, that the target market is large enough to matter, and that the company has more than one shot on goal.
In most sectors, going public implies a mature, revenue-generating business. Biotech breaks this pattern: because drug development is capital-intensive and takes a decade or more from discovery to approval, waiting for revenue would mean waiting for regulatory approval itself — often 8–12 years after a company is founded. Public markets instead price biotech companies on the probability-weighted value of their pipeline, discounted for the risk of clinical failure at each remaining stage.
This is why a pre-revenue, sometimes even pre-Phase-3 company can list successfully: what public investors are underwriting is not current cash flow but a data-driven thesis about future approval and peak sales. That thesis has to be strong enough, and de-risked enough, to be underwritten by institutional investors who will hold the stock through further binary clinical readouts after listing.
Not all positive data is IPO-ready data. Underwriters and the institutional investors they market to are typically looking for:
• Statistically and clinically meaningful effect sizes on a pre-specified primary endpoint, not just a favorable trend • A clean safety profile with no unresolved signals that could derail a later pivotal trial • Reproducibility — ideally more than one cohort or study showing a consistent effect • A clear translational story connecting the mechanism of action to the clinical result, so the data is defensible under scrutiny, not just a statistical outlier
Phase 2 proof-of-concept data is the traditional minimum bar because Phase 1 alone (safety, dosing) says little about whether a drug actually works, while waiting for Phase 3 or approval sacrifices years of access to public capital. A strong Phase 2 readout — especially in a company's lead indication — is frequently the single event that opens the door to a realistic IPO timeline.
The clinical data package is not just a scientific artifact — it becomes the centerpiece of the S-1 risk factors, the roadshow deck, and every analyst model built after listing. Its strength has an outsized, compounding effect on every later stage of the IPO process.
A company with a single clinical program, however promising, carries binary risk: one failed trial can erase most of its value overnight. Investors and underwriters therefore reward — and frequently require — evidence of pipeline depth: a second or third program in a related modality or indication, a validated platform technology that can generate future candidates, or partnerships that diversify how value can be created if the lead program stumbles.
The "differentiation" half of the story matters just as much as depth: in crowded therapeutic areas, being merely another entrant chasing the same target is a much harder sell than having a genuinely distinct mechanism, a first-or-best-in-class positioning, or an addressable population competitors have not targeted. Building this narrative — and having the data to support it — is typically the longest single lead-time item on the entire IPO-readiness roadmap.
| Product | Indication | Trial Design | Key Result |
|---|---|---|---|
| Clinical data package | R&D / Clinical Ops | Phase 2+ data underpins the entire equity story | |
| Audited financial statements | CFO / External Auditor | Multi-year audit trail required before filing | |
| SOX-ready internal controls | Finance / Legal | Section 404 compliance readiness | |
| Independent board & committees | Board / Legal | Governance credibility for public investors | |
| Underwriter selection & confidential filing | CFO / Legal / Bankers | Sets the registration statement in motion |
Great science alone does not make a company IPO-ready. Public markets require a level of financial rigor and governance structure that most private biotechs simply have not needed to build yet: multi-year audited financials, internal controls capable of surviving public-company scrutiny, and an independent board equipped to oversee a publicly traded entity. This buildout is unglamorous, expensive, and frequently underestimated in how long it takes.
Private biotechs often operate with lean finance teams and financial statements that, while adequate for board reporting and venture investors, were never built to withstand the scrutiny of public markets or a securities regulator's review. Preparing for an IPO typically means engaging a reputable external auditor well in advance, closing multiple years of financials to a public-company standard, and resolving any accounting inconsistencies retroactively — a process that can take a year or more if the historical books were not built with this end state in mind.
Certain emerging-growth-company provisions can reduce the number of audited fiscal years required relative to a fully seasoned filer, but the underlying expectation remains the same: by the time the registration statement is filed, the numbers must be clean, consistently applied, and defensible under audit-committee and regulator review.
Public companies are required to maintain, and eventually attest to, effective internal controls over financial reporting under the Sarbanes-Oxley Act. Building this control environment from scratch — documented processes, segregation of duties, systems that can produce auditable, timely financial reporting on a quarterly cadence — is a significant undertaking for an organization that has never operated on public-company timelines.
Many companies begin SOX-readiness work well before the IPO itself, often engaging outside consultants to design and test controls, because remediating control weaknesses discovered late in the process can materially delay a filing. The scope typically expands post-IPO (full management attestation, and eventually external auditor attestation, phase in over subsequent fiscal years for many issuers), but the control framework itself needs to be substantially built before the roadshow.
Internal-controls and financial-infrastructure work is rarely visible to outside observers of an IPO, but alliance and finance teams inside the company frequently describe it as the single most underestimated line item on the readiness timeline — harder to compress than almost any other workstream.
Private company boards are often dominated by founders and venture-capital investors. A public-ready board needs a majority of genuinely independent directors — individuals with no material financial relationship to the company beyond their board role — along with the specific committee structure public markets and exchange listing standards expect:
• Audit committee — composed entirely of independent directors, at least one qualifying as a financial expert, responsible for overseeing the audit relationship and financial reporting integrity • Compensation committee — independent oversight of executive pay, equity grants, and public-company compensation disclosure requirements • Nominating/governance committee — often added alongside the two required committees to formalize board composition and governance policy
Recruiting directors with relevant public-company, regulatory, or commercial biotech experience — and doing so early enough that they can meaningfully participate in pre-IPO governance decisions — is itself a multi-month process that many companies start a year or more before their target filing date.
With the clinical story and the governance infrastructure in place, the company selects the investment banks that will underwrite the offering and files an initial registration statement — most often on a confidential basis — with the securities regulator. This is the moment the process shifts from purely internal preparation to formal, though still private, regulatory engagement.
Choosing investment banks to underwrite an IPO is a formal, competitive process often called a "bake-off," in which candidate banks pitch their valuation approach, sector expertise, institutional investor relationships, and proposed syndicate structure. Companies typically select one or two lead bookrunners — who run the process and hold primary responsibility for pricing and allocation — alongside several co-managers who add distribution reach and sector credibility.
Banker selection is not purely about fees or headline valuation promises: the syndicate's existing relationships with the specialist healthcare-focused institutional investors who dominate biotech IPO order books, and its analysts' credibility in the therapeutic area, often matter more to the ultimate success of the offering than the initial pitch numbers.
Rather than filing a registration statement publicly from day one, eligible companies — most biotechs qualify as emerging growth companies — can submit an initial draft confidentially to the securities regulator for private review. This lets the company work through multiple rounds of regulator comments and refine sensitive disclosures (clinical data framing, competitive positioning, risk factors) without those drafts, or the fact that an IPO is even being contemplated, being visible to the public or competitors.
The regulator typically returns comment letters raising questions or requesting additional disclosure; the company and its counsel respond and revise, often across several rounds, until the staff signals it has no further comments. Only once the review is substantially complete does the company publicly file the registration statement — by rule, generally at least a set number of days before the roadshow begins — converting what was previously a private process into public information available to any investor.
Confidential draft submission exists precisely so that a company can test the regulatory and disclosure waters — and even change its mind about proceeding — without ever having to publicly announce a withdrawn or delayed IPO, which can be reputationally and commercially costly.
Regulatory comments on a draft registration statement typically focus on ensuring disclosure is complete, balanced, and not misleading — not on judging whether the company's science or business plan is good. Common areas of focus for biotech filers include: whether clinical trial result descriptions are presented with appropriate context and are not selectively favorable, whether risk factors adequately describe the real probability and consequence of clinical or regulatory failure, and whether financial statement presentation and non-GAAP metrics are properly reconciled and explained.
Resolving these comments is iterative and can take weeks to a few months depending on complexity. Legal and finance teams treat this as a critical-path item precisely because the roadshow — and the public disclosure that goes with it — cannot begin until the staff has finished its review.
Once the registration statement is public, the company's leadership — typically the CEO and CFO, accompanied by the lead underwriters — spends one to two intense weeks presenting the investment case directly to institutional investors across multiple cities. In parallel, the underwriters run a formal book-building process, collecting real-time indications of demand that ultimately determine the final offering price.
The roadshow is a compressed, high-intensity sales process aimed at the institutional investors — mutual funds, hedge funds, specialist healthcare funds — who will make up the bulk of the initial shareholder base. Management delivers a standardized presentation dozens of times across back-to-back one-on-one and small-group meetings, typically spanning several major financial centers over one to two weeks, supplemented by video calls for investors who cannot be met in person.
The content mirrors the registration statement but is delivered as a persuasive narrative: the clinical data, the market opportunity, the differentiation story, the leadership team's credibility, and the use of proceeds. Because public statements during this period are tightly constrained by securities law (the traditional "quiet period" concept, considerably narrowed but not eliminated by later reforms), management is trained extensively beforehand on what can and cannot be said outside the four corners of the prospectus.
Throughout the roadshow, the underwriters' sales desks collect indications of interest from institutional investors: how many shares an investor would buy, and at what price within (or sometimes outside) the preliminary price range printed on the prospectus cover. This running tally is the "order book."
As meetings progress, the underwriters watch not just the total size of the book but its quality and composition: are the orders coming from long-term, fundamentals-driven specialist investors likely to hold the stock, or from short-term participants likely to sell immediately after listing? A book that is several times oversubscribed by high-quality accounts gives the underwriters room to price at or above the initial range; soft demand can force a lower price, a reduced share count, or in rare cases a postponed offering altogether.
Book-building is fundamentally a price-discovery mechanism, not a fixed-price sale — the final IPO price is set only after the roadshow closes, based on the shape of real demand the underwriters observed, not on a number decided in advance.
The roadshow culminates in a single pricing decision, typically made the evening before trading begins, followed the next morning by the ceremonial first trade. But going public is not the finish line — it is the start of an ongoing set of public-market obligations, including a lock-up period that restricts how soon insiders can sell, and a continuous cycle of disclosure the company must now sustain indefinitely.
On the evening the roadshow concludes, the company's board (often via a pricing committee) and the lead underwriters review the completed order book and agree on a final offering price and share count. This decision balances several tensions at once: pricing too low leaves money on the table for the company and existing shareholders; pricing too high risks a weak or negative first-day trading reaction that can damage the stock's reputation with the very institutional holders it needs for the long term.
Once set, the final prospectus is filed reflecting the actual price, and shares are allocated to investors across the order book — typically favoring the long-term, fundamentals-driven accounts the underwriters most want as the company's early public shareholder base.
On the morning of listing, the exchange runs an opening auction process to match buy and sell orders and establish the first public trade — often marked by a ceremonial bell-ringing. Because the offer price was set the night before based on a necessarily incomplete picture of total market demand, the stock's opening trade and subsequent first-day movement represent genuine, real-time price discovery, and can move meaningfully away from the offer price in either direction.
Substantial early volatility is common and does not by itself indicate a mispriced offering; underwriters and company management typically watch the first several weeks of trading, not just the first day, before drawing conclusions about how the market has received the story.
Underwriting agreements almost universally include a lock-up provision — commonly around 180 days, though terms vary — that restricts company insiders, founders, and pre-IPO investors from selling their shares immediately after listing. The purpose is to prevent a flood of insider selling from overwhelming the newly public, still-thin trading market and to signal insider confidence in the offering price. Its scheduled expiration is itself a well-known event that can add selling pressure and volatility when it arrives.
Beyond the lock-up, going public converts every readiness workstream built in earlier stages into a permanent operating obligation: quarterly and annual financial reporting, continuous material-event disclosure, ongoing SOX compliance and audit-committee oversight, and a board and management team now directly accountable to public shareholders for every subsequent clinical, regulatory, and commercial milestone.
Everything built in Stages 1 through 4 — the data package, the audited financials, the governance structure, the underwriter relationships — does not become obsolete at listing. It becomes the permanent operating infrastructure the company now has to sustain, quarter after quarter, as a public company.